详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

First-Line Afatinib versus Gefitinib in EGFRm plus Advanced NSCLC: Updated Overall Survival Analysis of LUX-Lung 7

文献详情

资源类型：

作者：

机构： [1]Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea; [2]Natl Canc Ctr, Med Oncol, Singapore, Singapore; [3]Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China; [4]McGill Univ, Montreal, PQ, Canada; [5]Princess Alexandra Hosp, Brisbane, Qld, Australia; [6]Queensland Univ Technol, Brisbane, Qld, Australia; [7]Chris OBrien Lifehouse, Camperdown, NSW, Australia; [8]Natl Taiwan Univ Hosp, Taipei, Taiwan; [9]Natl Taiwan Univ Canc Ctr, Taipei, Taiwan; [10]Chinese Univ Hong Kong, Key Lab South China, Hong Kong, Hong Kong, Peoples R China; [11]Chungbuk Natl Univ Hosp, Cheongju, Chungbuk, South Korea; [12]Shanghai Chest Hosp, Shanghai, Peoples R China; [13]Chinese Acad Med Sci, Natl Canc Ctr, Canc Hosp, Beijing, Peoples R China; [14]Peking Union Med Coll, Beijing, Peoples R China; [15]Beijing Key Lab Clin Study Anticanc Mol Targeted, Beijing, Peoples R China; [16]Asan Med Ctr, Seoul, South Korea; [17]BC Canc Agcy, Vancouver, BC, Canada; [18]Seoul Natl Univ Hosp, Seoul, South Korea; [19]Ottawa Hosp, Canc Ctr, Ottawa, ON, Canada; [20]Karolinska Univ Hosp, Stockholm, Sweden; [21]Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA; [22]Boehringer Ingelheim Ltd Uk, Bracknell, Berks, England; [23]Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany; [24]Hosp Univ Doce Octubre & Cnio, Madrid, Spain

出处：

ISSN：

关键词： afatinib gefitinib NSCLC EGFR

语种：

被引次数：

WOS：

中科院(CAS)分区：

出版当年[2017]版：

大类 | 2 区医学

小类 | 2 区肿瘤学 2 区呼吸系统

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学 1 区呼吸系统

第一作者：

第一作者机构： [1]Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea;

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Afatinib versus Gefitinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients Aged >= 75 Years: Subgroup Analysis of LUX-Lung 7 [2]Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial [3]Sequential Afatinib-Osimertinib Therapy in EGFR Mutation-Positive (EGFRm plus ) NSCLC: Analysis of Time on Treatment and OS [4]Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non-Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials [5]Afatinib (A) vs gefitinib (G) in patients with EGFR mutation-positive (EGFRm1) NSCLC: Updated OS data from the phase IIb trial LUX-Lung 7 (LL7) [6]Afatinib vs gefitinib for treatment-naive patients with EGFRm1 NSCLC (LUX-Lung 7): Analysis of time to treatment failure and impact of afatinib dose adjustment [7]Gefitinib as First-Line Treatment of Plasma CtDNA EGFR Mutation-Positive NSCLC Detected by DdPCR: BENEFIT Study (CTONG1405) [8]Afatinib vs gefitinib in patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7) [9]Afatinib as a Potential Therapeutic Option for Patients With NSCLC With EGFR G724S. [10]Rare EGFR E709-T710delinsX: Molecular characteristics and superior response to afatinib treatment in NSCLC patients